NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT00937417 2017-04-24S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid TumorsSWOG Cancer Research NetworkPhase 1 Withdrawn